Editor Insights

Winston Wong, PharmD, contends that CMMI needs to reexamine their current surrogate and direct measures of quality with the goal that, in the future, interoperability and expanded datasets will allow true measurement of quality of care.

Winston Wong, PharmD, reviews the current treatment options for CLL and argues that until real-world evidence trials occur, it is difficult to determine whether meaningful improvement has occurred in clinical outcomes and quality of life as a...

Winston Wong, PharmD, argues that under the current ICER value assessment framework and QALY measurements, there may never be a transformative therapy that demonstrates cost-effectiveness.

Winston Wong, PharmD, breaks down the ASCO position statement on the utilization of biosimilars in oncology and ways in which the anticipated cost-savings may be achieved.

As with so many other key words in health care today, there is no standard definition of what “value-based oncology care” entails; it is subject to different interpretations from payers, providers, and patients, according to Winston Wong,...